Ignite Creation Date:
2024-05-06 @ 2:59 AM
Last Modification Date:
2024-10-26 @ 11:26 AM
Study NCT ID:
NCT02175056
Status:
COMPLETED
Last Update Posted:
2015-10-06
First Post:
2014-06-17
Brief Title:
A Dose-Block Randomized Placebo Controlled Double-blind Active ControlledOpen-label Dose-escalation Study
Sponsor:
Handok Inc
Organization:
Handok Inc
Study Overview
Official Title:
A Dose-Block Randomized Placebo Controlled Double-blind Active ControlledOpen-label Dose-escalation Study to Investigate the Tolerability and PharmacokineticsPharmacodynamics of HL2351 After a Single Subcutaneous Administration in Healthy Male Subjects
Status:
COMPLETED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study design of this trial is a Dose-Block Randomized Placebo controlled Double-blind Active ControlledOpen-label Dose-escalation
Detailed Description:
Extended in vivo half-life of HL2351 is also anticipated to provide improved therapeutic efficacy based on sustained maintenance of an effective concentration
A safety concern may be addressed by utilizing IL-1Ra that is being used after getting approval by the EMA and the US FDA and known to be relatively safe and the Fc fusion technology that has been already applied to various therapeutic agents
A safety concern may be addressed by utilizing IL-1Ra that is being used after getting approval by the EMA and the US FDA and known to be relatively safe and the Fc fusion technology that has been already applied to various therapeutic agents
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None